Home Scleroderma
Cell Star

Scleroderma

Scleroderma, also known as systemic sclerosis, is a rare, chronic autoimmune connective tissue disease characterized by abnormal growth of connective tissue and fibrosis (hardening) of the skin and internal organs. The condition results from excessive collagen production and accumulation, leading to thickening and hardening of the skin and affecting blood vessels, muscles, and organs such as the lungs, heart, kidneys, and digestive tract.

Scleroderma primarily affects adults, particularly women aged 30 to 50, and can range from localized forms with limited skin involvement to systemic forms with potentially life-threatening organ complications. Though there is no cure, advances in treatment and supportive care are improving outcomes and quality of life for many patients.

Types of Scleroderma

Localized Scleroderma:

  • Morphea: Localized patches of hardened skin.
  • Linear scleroderma: Affects skin and underlying tissues along a line, often on limbs or the face.

Systemic Sclerosis (Systemic Scleroderma):

  • Limited cutaneous systemic sclerosis (lcSSc): Skin thickening confined to the hands, arms, and face; associated with CREST syndrome (Calcinosis, Raynaud’s phenomenon, Esophageal dysfunction, Sclerodactyly, Telangiectasia).
  • Diffuse cutaneous systemic sclerosis (dcSSc): More widespread skin involvement and higher risk of internal organ complications, especially lungs, kidneys, and heart.

Causes and Risk Factors

The exact cause of scleroderma is unknown. It is believed to result from a combination of genetic, immune, and environmental factors.

  • Autoimmune response: The immune system mistakenly attacks the body’s own tissues, leading to inflammation and fibrosis.
  • Genetic predisposition: Certain gene variations may increase susceptibility.
  • Environmental triggers: Exposure to silica dust, certain solvents, or infections may initiate or worsen the disease.
  • Gender: Women are four times more likely to develop scleroderma than men.

Pathophysiology

Scleroderma is marked by three key pathological features:

  • Vascular abnormalities: Damage to small blood vessels (microangiopathy) causes narrowing and reduced blood flow, particularly evident in Raynaud’s phenomenon.
  • Immune system activation: Abnormal immune responses lead to chronic inflammation.
  • Fibrosis: Excess collagen and extracellular matrix are deposited in the skin and organs, leading to thickening and loss of function.

These processes can cause severe complications, including pulmonary arterial hypertension, interstitial lung disease, and scleroderma renal crisis.

Symptoms

Symptoms vary depending on the form and severity of the disease:

Skin involvement:

  • Thickening, tightening, and hardening of the skin
  • Shiny or discolored patches
  • Limited mobility in affected areas

Vascular symptoms:

  • Raynaud’s phenomenon (fingers and toes turning white or blue in cold or stress)
  • Telangiectasia (spider-like red spots on skin)

Gastrointestinal symptoms:

  • Difficulty swallowing
  • Acid reflux.
  • Bloating, diarrhea, or constipation

Musculoskeletal symptoms:

  • Joint pain or stiffness
  • Muscle weakness

Pulmonary involvement:

  • Shortness of breath
  • Dry cough

Renal symptoms:

  • High blood pressure
  • Scleroderma renal crisis (sudden kidney failure)

Cardiac symptoms:

  • Arrhythmias
  • Heart failure

Diagnosis

Diagnosis is based on clinical presentation, laboratory tests, and imaging:

Physical exam: Skin changes, joint stiffness, Raynaud’s phenomenon

Autoantibody tests:

  • ANA (antinuclear antibodies)
  • Anti-centromere antibodies (common in lcSSc)
  • Anti-Scl-70 (associated with dcSSc and lung disease)
  • Anti-RNA polymerase III (linked to renal crisis)

Imaging:

  • HRCT (high-resolution CT) for lung fibrosis
  • Echocardiogram for pulmonary hypertension
  • Endoscopy for GI involvement

Pulmonary function tests: To evaluate lung capacity and function

Kidney function tests: Serum creatinine and urinalysis

Conventional Treatment

There is no cure for scleroderma, but treatment focuses on managing symptoms, slowing disease progression, and preventing complications.

Immunosuppressive drugs:

  • Methotrexate, mycophenolate mofetil, cyclophosphamide

Biologic therapies:

  • Rituximab, tocilizumab (target specific immune pathways)

Vasodilators:

  • Calcium channel blockers (e.g., nifedipine) for Raynaud’s
  • Endothelin receptor antagonists, PDE-5 inhibitors for pulmonary hypertension

Proton pump inhibitors (PPIs): For acid reflux

ACE inhibitors: For scleroderma renal crisis

Antifibrotic agents: Such as nintedanib, used in interstitial lung disease

Treatment is tailored to individual organ involvement and disease severity.

Stem Cell Therapy in Scleroderma

Stem cell therapy, particularly hematopoietic stem cell transplantation (HSCT), is being explored in severe, progressive systemic sclerosis.

Types of stem cells:

  • Hematopoietic stem cells (autologous transplantation)
  • Mesenchymal stem cells

Mechanism of action:

  • Resetting the immune system
  • Reducing autoantibody production
  • Promoting tissue regeneration and vascular repair

Clinical evidence:

  • The ASTIS and SCOT trials demonstrated improved skin and lung function in HSCT-treated patients

Hyperbaric Oxygen Therapy (HBOT) for Scleroderma

HBOT is a potential supportive treatment, particularly for chronic skin ulcers and ischemic complications.

Mechanism:

  • Enhances oxygen delivery to hypoxic tissues
  • Promotes angiogenesis and fibroblast activity
  • Reduces inflammation and oxidative stress

Applications:

  • Healing of digital ulcers in Raynaud’s
  • Pain relief and improved skin integrity
  • May enhance quality of life in some cases

Lifestyle and Holistic Management

  • Skin care: Moisturizers to prevent dryness and cracking
  • Protective clothing: Gloves and thermal wear for Raynaud’s
  • Nutrition: Balanced diet, avoid reflux triggers
  • Physical therapy: Maintain joint mobility and muscle strength
  • Mental health: Counseling and support groups for coping with chronic illness

Prognosis

Prognosis varies depending on the extent and rate of progression. Patients with limited cutaneous disease often have a better outlook, while those with diffuse disease and organ involvement face higher risks. Early diagnosis and aggressive management improve survival and quality of life.

Conclusion

Scleroderma is a complex autoimmune disease with wide-ranging symptoms and potential for serious complications. Though there is no cure, emerging therapies such as stem cell treatment and hyperbaric oxygen therapy offer new hope. A personalized, multidisciplinary approach that includes medication, rehabilitation, and lifestyle interventions is essential to managing disease progression, minimizing complications, and enhancing patient well-being.

Working Time
  • Monday-Saturday 09:00 AM  TO 06:00 PM
Contact Info